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Hemophilia B is a rare X-linked recessive disorder with plasma factor IX (FIX) deficiency. 1-3% of patients treated
with exogenous FIX-containing products develop inhibitors (i.e. polyclonal high affinity immunoglobulins) that
neutralize the procoagulant activity of a specific coagulation factor. Although the incidence of inhibitors in
hemophilia B patients is low, most are “high titer” and frequently associated with the development of severe allergic
or anaphylactic reactions. Immune tolerance induction as a strategy for inhibitor eradication was first described in
1984. Unfortunately, the overall reported success of immune tolerance induction in FIX deficiency with inhibitors is
approximately 25-40%.
We report the case of a 2-year-old boy with hemophilia B severe FIX deficiency (<1%), inhibitor antibodies to FIX
development, and a history of adverse reactions to FIX infusions, who underwent a successful desensitization and
immune tolerance induction with a daily FIX infusion. With this regimen the inhibitor titer decreased with effective
bleeding prevention.
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Among people with hemophilia, approximately 80% have
hemophilia A, whereas only 20% have hemophilia B.
Hemophilia B is an inherited, X-linked, recessive dis-
order which results in a deficiency of functional factor
IX plasma coagulation. It occurs in approximately one
to 30,000 male births, in all populations. Mutations
causing this disorder have been found all over the FIX
gene located in Xq27.1 [1].
Based on the coagulation factor in the patient’s
plasma, hemophilia may be classified as mild (>5%), mo-
derate (1-5%) or severe (<1%). About 30 - 45% of pa-
tients with hemophilia B have a severe disease [2],
requiring prophylactic or on-demand replacement the-
rapy to prevent major and minor bleeding. The use of* Correspondence: f.mori@meyer.it
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lation factor products, followed by recombinant factor
IX concentrates, lowered the risk of severe bleeding and
the transmission of infectious agents, so that the deve-
lopment of inhibitory antibodies is nowadays the most
serious complication found in hemophilia B patients [2].
Inhibitors
An inhibitory antibody is a polyclonal high affinity im-
munoglobulin that neutralizes the procoagulant activity
of a specific coagulation factor. Inhibitor levels are mea-
sured using Bethesda Units (BU), and classified as “high
titer” (≥5 BU) or “low titer” (<5BU) [2].
Genetics influences the risk associated to the develop-
ment of inhibitory antibodies. Missense mutations in the
FIX gene have almost no risk of inhibitor development
[3], whereas large deletions and frame-shift mutations
leading to the loss of coding information are much more
likely to be associated to it. Large deletions account foris is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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50% of inhibitor patients [1].
It has been postulated that the complete absence of
endogenous factor IX protein leads to the induction of
inhibitors after exposure to an exogenous factor IX anti-
gen. Associated deletion of neighboring genes can con-
tribute to this phenomenon [4]. Additionally, individuals
with complete gene deletions were found to be at greater
risk of anaphylaxis. Thus, genetic analysis at birth could
be important for identifying those at risk for inhibitors
and possible anaphylaxis development.
For determining an inhibitor production risk, immune
response genes, environmental factors, and other im-
mune system challenges may play a role [5,6].
The development of inhibitory antibodies is seen in
about 30% of patients with severe hemophilia A but only
1-3% of those with hemophilia B [7]. The reason why is
unknown, but a structural analogy to other vitamin
K-dependent factors may confer some tolerance to FIX.
Moreover, approximately 60% of severe hemophilia B
results from missense mutations [8], providing an in-
creased proportion of antigenic determinants of FIX and
letting the “exogenous” FIX be recognized as itself. The
majority of people with hemophilia B who develop in-
hibitors have a severe disease.
Although the incidence of inhibitors in hemophilia B
patients is low, most are “high titer” and frequently asso-
ciated with the development of severe allergic or ana-
phylactic reactions, whereas anaphylactic reactions in
hemophilia A patients with FVIII inhibitors almost never
occur. One hypothesis explaining this difference could be
that the smaller FIX molecular weight makes its distribu-
tion possible in both intra and extravascular space com-
pared to FVIII, which stays confined to the intravascular
space [7]. The extravascular distribution may facilitate mast
cell activation and IgE mediated hypersensitivity [2]. An-
other possible reason is the exposure to higher amounts of
exogenous FIX because of the higher than normal concen-
tration in plasma, 5 μg mL−1 vs 0,1 μg mL−1 of FVIII [2].
Patients with severe hemophilia B are at particular risk
for the sudden development of anaphylactic shock or
other severe allergic reaction and inhibitor development:
while these two events are often closely related tempor-
ally, one may precede the other. The development of a
FIX inhibitor exposes the patient at greater risk of ana-
phylaxis with one of his subsequent doses [1].
For the risk of potentially life-threatening reactions it
has been suggested that all infants and small children
with severe hemophilia B be closely monitored over their
first 20 or more infusions with any FIX-containing
product in a facility equipped to treat anaphylactic
shock [9-11].
Most individuals who develop an inhibitor to FIX do
so relatively early in life (within the first 4–5 years), aftera median of 9–11 exposure days (EDs) to any FIX-
containing product [1].
Data from the international registry organized by
Warrier et al. [2] on behalf of the FVIII/FIX Subcommittee
of the International Society on Thrombosis and Hemostasis
(ISTH)’s Scientific and Standardization Committee (SSC),
didn’t find differences in anaphylactic and severe aller-
gic reactions following exposure to intermediate-purity or
high-purity (either recombinant or plasma-derived) FIX
products.Biological mechanisms
IgE-mediated [12] and non-IgE-mediated mechanisms
may be involved. IgG1 and IgG4 subclasses were found
at the time of anaphylactic reaction in some patients
with inhibitors and a history of anaphylaxis [13]. The de-
velopment of specific IgG inhibitors may subsequently
lead to a complete activation of anaphylatoxins and the
release of mediators from mast cells [14]. Murine models
show that anaphylaxis may occur in an IgE-independent
manner, involving specific IgG, FcgRIII, macrophages, ba-
sophils, and the platelet-activating factor (PAF) as the
major mediator [15].Treating patients with inhibitors
Treatment of individuals with FIX deficiency compli-
cated by inhibitors can be divided into two categories:
strategies for treatment and/or prevention of acute
bleeding and strategies for inhibitor eradication.
Treatment of hemorrhagic episodes in patients with
FIX deficiency complicated by inhibitors depends upon
the type of bleeding episode, the inhibitor classification
(high- vs low-responding, more or less than 5 BU re-
spectively after repeated exposure), and the history and
severity of previous infusion reactions.
Administrating FIX to overcome inhibitor titer and
achieve hemostatic levels is an option in patients with
low-responding inhibitors without previous infusion
reactions. Unfortunately, such patients represent a
minority.
In patients with high-responding inhibitors and/or
previous infusion reactions, the mainstays of treatment
(or prevention) of bleeding episodes are activated re-
combinant factor VII concentrate (rFVIIa) and plasma-
derived activated prothrombin complex concentrates
(aPCCS). rFVIIa is a recombinant product, and has ge-
nerally proven to be safe and effective, even if it is ex-
pensive and has a short half-life [16,17].
Plasmapheresis or immunoadsorption with staphylo-
coccal protein A may be considered in patients with
high inhibitor titers experiencing life-threatening blee-
ding and are unresponsive to other therapies where
using an FIX concentrate would be life- or limb-saving.
Table 1 Factor IX desensitization protocol (modified from
Dioun et al. [12])
Dose (U/kg) Cumulative
dose (U/kg)
Infusion
time
Interval from
previous
dose (min)
Day 1 0.01 0.01 5 min 0
0.02 0.03 5 min 10
0.04 0.07 5 min 10
0.08 0.15 5 min 10
0.10 0.25 5 min 10
0.02 0.45 5 min 20
0.04 0.85 5 min 20
0.08 1.65 5 min 20
1.5 3.15 5 min 20
3 6.15 30 min -
6 12.15 30 min -
9 21.15 60 min -
10 31.15 60 min -
Day 2 40 40 10 h -
Day 3 40 40 8 h -
Day 4 40 40 6 h -
Day 5 40 40 4 h -
Day 6 40 40 2 h -
Day 7 40 40 1 h -
Day 8 40 40 30 min -
Day 9 40 40 20 min -
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ITI as a strategy for inhibitor eradication was first
described by Brackmann in 1984 in hemophilia A [18].
There is little data for developing a useful and evidence-
based approach to the prevention and eradication of FIX
inhibitors [19] due to the small numbers in hemophilia
B compared to hemophilia A. Unfortunately, the overall
reported success of ITI in FIX deficiency with inhibitors
is approximately 25-40% [2].
Often patients with high titer inhibitors have a history
of severe allergic reactions and anaphylaxis to FIX infu-
sion (allergic phenotype) and need desensitization with
gradually increased doses of FIX prior to ITI. Dioun
et al. [12] have described a successful desensitization
protocol involving skin testing to FIX-containing pro-
ducts; this was followed by an infusion lasting several
hours, and was the base of our desensitization protocol.
Some successful desensitization protocols with or without
immune modulation have been reported, such as the use
of plasmapheresis, or an addition of steroids or rituximab
before, during or after the escalating dose [12,20-22].
We report the case of a 2-year-old boy with severe
FIX-deficiency (<1%), inhibitor development, and a his-
tory of adverse reactions to FIX infusions, who under-
went a successful desensitization and ITI.
Case presentation
We report the case of a 2-year-old boy who was diag-
nosed with severe FIX deficiency at 9 months of age
after testing due to frequent bruising of the skin. The
genetic analysis reported a nonsense mutation of the
FIX gene. Recombinant FIX (BeneFIX®, rFIX) was started
on demand, and the young patient was treated several
times without complications. At 1 year of age the patient
developed pallor, sweating, agitation and then fainting
during rFIX infusion. The patient recovered within mi-
nutes after suspending therapy. There was no rash or
respiratory distress. The next day the infusion was re-
peated and the patient exhibited a transient perioral
cyanosis and agitation, but therapy was completed with-
out other complications. Blood tests revealed an initial
inhibitor titer of 2.7 Bethesda Units (BU), with a peak of
25 BU one month later.
For this reason and for fear of severe adverse reactions,
BeneFIX® was stopped and bleeding episodes were trea-
ted with a recombinant factor VII concentrate (rFVIIa,
NovoSeven®). Response was suboptimal even with high
doses (230 μg/kg) with very frequent bleeding.
For the declining quality of life, with the purpose of
re-introducing factor IX, the patient was admitted to our
center at 23 months of age. Inhibitor titer was 0,1 BU.
The skin prick test with FIX concentrate was negative,
with normal saline and histamine used as negative and
positive controls, respectively. Intradermal tests withfactor IX concentrate in 1:100 and 1:10 dilution were
also negative, with a negative control of normal saline.
Thus, we performed a challenge test by infusing 30 U/kg
of FIX diluted in 50 mL of normal saline for 20 minutes,
then 120 U/Kg diluted in 10 mL for 20 minutes without
any reaction.
Therefore the dosage of 150 U/Kg was initially main-
tained daily, then every 2 or 3 days. During his fifth dose
he developed a new reaction with agitation, cough, facial
hyperemia and then cyanosis, soon after starting the
infusion. He was treated with hydrocortisone with a
complete resolution of the symptoms. The inhibitor titer
was 37 BU and peaked at 60 BU three days later.
The sudden and unexpected reaction with respiratory
involvement and the concomitant rise in the inhibitor
titer discouraged us from continuing this approach, so
we stopped the FIX.
At that point we started a desensitization protocol
with increasing FIX doses to allow us to start an ITI
regimen (Table 1). After the first dose (0,01 U/kg) the
patient manifested agitation, mild facial hyperemia with-
out respiratory involvement. Nevertheless, the desensi-
tization was continued and the subsequent doses were
well tolerated without any adverse effects.
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Figure 1 The inhibitor titer after the challenge, during FIX infusion, desensitization and ITI regimen. C: Challenge with rFIX; D: desensitization;
AR: adverse reaction, BU: Bethesda Unit.
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without reactions, and the inhibitor level is slowly de-
creasing (Figure 1).Conclusion
In this case report our patient with severe haemophilia
B developed inhibitors and adverse reactions to the FIX
infusion. Biological mechanisms of immune tolerance
in hemophilia patients are largely unknown, and derive
from studies on hemophilia A. The development of
anti-idiotypic antibodies, T-cell anergy and inhibi-
tion of memory B cell differentiation possibly play a
role [23].
The way the drug is administered is perhaps important
in developing inhibitors and tolerance induction. Studies
on biological drugs show that patients receiving episodic
treatment develop anti-drug-antibodies more frequently
than those receiving scheduled therapy [24]. Consistent
to this observation, the patient developed an inhibitor
and allergic reactions when treated episodically, but with
daily scheduled infusion inhibitor titer is decreasing and
the therapy is well tolerated.
Desensitization opens the way to an ITI, using daily or
larger daily doses of FIX every other days.
In particular, a desensitization protocol allowed us to
start ITI with a daily FIX infusion. In our ITI regimen,
40 U/kg (500 U) given once daily were sufficient to
decrease the inhibitor titer and to control bleeding. The
dose is considerably lower than that used in other pub-
lished studies [21,22], although it was equally effective.Even when effective, ITI can present severe complica-
tions such as nephrotic syndrome, typically 8–9 months
into therapy. It is more frequent in patients with pre-
vious infusion reactions to FIX (allergic phenotype).
Frequently it is nonresponsive to steroids and requires
the suspension of ITI [2]. Renal biopsies demonstrated
membranous glomerulonephritis in two patients [25-27].
In this case follow up is not long enough and immune
tolerance not achieved yet so it is not possible to know
whether the patient would develop nephrotic syndrome.
Consent
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